Why Is RAPPORT THERAPEUTICS Equity (RAPP) Stock Down Today?

Rapport Therapeutics shares fell 18.30% to close at $22.50. The primary driver was the announcement of a $350 million capital raise, which included separate offerings of common stock and convertible senior notes.

What Happened

Rapport Therapeutics priced underwritten offerings of common stock and pre-funded warrants alongside a concurrent private placement. The company announced a $200 million common stock offering and a $150 million offering of 2.25% convertible senior notes due 2032. The common stock was priced at $21.00 per share, while pre-funded warrants were priced at $20.999. This fundraising package was designed to support the clinical-stage biotechnology company’s development pipeline.

What The Data Shows

The stock’s 52-week range spans from $23.75 to $52.93, placing the current price near the bottom of that interval. Over the last eight sessions, the stock declined 21.3%, moving from $28.60 to $22.50. The company remains unprofitable with a trailing twelve-month EPS of negative $3.05 and a market capitalization of $1.2 billion. Its beta of 1.22 indicates higher volatility relative to the broader market.

Recent SEC Form 4 filings show mixed insider activity over the last 90 days, with six buys totaling $1.7 million and nine sells totaling $6.9 million. Directors Ramiro Sanchez, John Maraganore, and Paul M. Silva each recorded purchases in late October. Retail traders on social platforms have noted the recent director buying, though the overall crowd sentiment has deteriorated over the past week. The stock printed four fresh 52-week highs and eight fresh 52-week lows on October 28, 2026.

What To Watch

Investors will monitor the company’s upcoming earnings date for further updates on its clinical progress and capital allocation strategy.